Ferrer continues to evolve. Not to conform to prevailing market trends or to meet externally imposed regulatory requirements. But because the world around us is changing too, and because our responsibility within it is becoming ever clearer.
Over the past few years, we have evolved as a company guided by a single purpose: using business to fight for social justice. That transformation is still underway. It shapes how we treat people, how we engage with communities, and how we understand our impact on the planet.
But there is a parallel transformation underway. One that is becoming increasingly central to who we are as a company.
Our commitment to social justice leads us, as a pharmaceutical company, to focus on the areas where the need is greatest and solutions are most scarce. In particular, we are directing our efforts towards rare and debilitating diseases in which patients and their families have historically been underserved. Specifically, we focus on pulmonary vascular and interstitial lung diseases, as well as rare neurological disorders.
This does not take us away from our purpose. It is how we bring it to life.
What we choose to research, where we invest, and which patients we prioritize are not neutral decisions. They reflect what we value. For us, innovation is not just about advancing science or expanding our pipeline. It is about contributing to more equitable access to healthcare and addressing unmet medical needs in a meaningful way.
Bringing these two transformations together is not easy. It requires aligning our culture, our science, and the way we make decisions. It means balancing long-term ambition with immediate responsibilities.
We need to transform knowledge into solutions that change lives, reaching the people who need them most. That means keeping patients, their families, and their caregivers at the center of every decision.
There is still much work to be done. But we are strengthening our scientific capabilities, building partnerships, and turning our purpose into tangible outcomes. Words alone are not enough. We must prove it, step by step.
